27832198|t|Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology
27832198|a|Southeast Asia is an epicenter of multidrug-resistant Plasmodium falciparum strains. Selective pressures on the subcontinent have recurrently produced several allelic variants of parasite drug resistance genes, including the P. falciparum chloroquine resistance transporter (pfcrt). Despite significant reductions in the deployment of the 4-aminoquinoline drug chloroquine (CQ), which selected for the mutant pfcrt alleles that halted CQ efficacy decades ago, the parasite pfcrt locus is continuously evolving. This is highlighted by the presence of a highly mutated allele, Cam734 pfcrt, which has acquired the singular ability to confer parasite CQ resistance without an associated fitness cost. Here, we used pfcrt -specific zinc-finger nucleases to genetically dissect this allele in the pathogenic setting of asexual blood-stage infection. Comparative analysis of drug resistance and growth profiles of recombinant parasites that express Cam734 or variants thereof, Dd2 (the most common Southeast Asian variant), or wild-type pfcrt, revealed previously unknown roles for PfCRT mutations in modulating parasite susceptibility to multiple antimalarial agents. These results were generated in the GC03 strain, used in multiple earlier pfcrt studies, and might differ in natural isolates harboring this allele. Results presented herein show that Cam734 -mediated CQ resistance is dependent on the rare A144F mutation that has not been observed beyond Southeast Asia, and reveal distinct impacts of this and other Cam734 -specific mutations on CQ resistance and parasite growth rates. Biochemical assays revealed a broad impact of mutant PfCRT isoforms on parasite metabolism, including nucleoside triphosphate levels, hemoglobin catabolism and disposition of heme, as well as digestive vacuole volume and pH. Results from our study provide new insights into the complex molecular basis and physiological impact of PfCRT -mediated antimalarial drug resistance, and inform ongoing efforts to characterize novel pfcrt alleles that can undermine the efficacy of first-line antimalarial drug regimens.
27832198	0	9	Evolution	T045	C0015219
27832198	13	20	Fitness	T045	C3824713
27832198	21	33	Cost-Neutral	T033	C0243095
27832198	34	40	Mutant	T049	C0596988
27832198	41	46	PfCRT	T116,T123	C0962247
27832198	58	71	P. falciparum	T204	C0032150
27832198	72	88	4-Aminoquinoline	T109,T121	C0048060
27832198	89	104	Drug Resistance	T038	C0013203
27832198	123	130	Altered	T169	C0392747
27832198	131	139	Parasite	T204	C0030498
27832198	140	150	Metabolism	T040	C0025519
27832198	155	172	Digestive Vacuole	T026	C1167024
27832198	173	183	Physiology	T091	C0031842
27832198	184	198	Southeast Asia	T083	C0003983
27832198	218	237	multidrug-resistant	T032	C0242640
27832198	238	267	Plasmodium falciparum strains	T204	C0032150
27832198	343	350	allelic	T028	C0002085
27832198	351	359	variants	T028	C0678941
27832198	363	371	parasite	T204	C0030498
27832198	372	387	drug resistance	T038	C0013203
27832198	388	393	genes	T028	C0017337
27832198	409	457	P. falciparum chloroquine resistance transporter	T028	C0017337
27832198	459	464	pfcrt	T028	C0017337
27832198	487	497	reductions	T061	C0441610
27832198	505	515	deployment	T052	C2825812
27832198	523	539	4-aminoquinoline	T109,T121	C0048060
27832198	540	544	drug	T121	C1254351
27832198	545	556	chloroquine	T109,T121	C0008269
27832198	558	560	CQ	T109,T121	C0008269
27832198	586	592	mutant	T028	C0678941
27832198	593	598	pfcrt	T028	C0017337
27832198	599	606	alleles	T028	C0002085
27832198	619	621	CQ	T109,T121	C0008269
27832198	622	630	efficacy	T080	C1280519
27832198	648	656	parasite	T204	C0030498
27832198	657	662	pfcrt	T028	C0017337
27832198	663	668	locus	T082	C1708726
27832198	736	742	highly	T080	C0205250
27832198	743	750	mutated	T045	C0026882
27832198	751	757	allele	T028	C0002085
27832198	759	771	Cam734 pfcrt	T028	C0017337
27832198	823	831	parasite	T204	C0030498
27832198	832	834	CQ	T109,T121	C0008269
27832198	835	845	resistance	T038	C0013203
27832198	868	875	fitness	T045	C3824713
27832198	876	880	cost	T080	C4049986
27832198	896	901	pfcrt	T028	C0017337
27832198	912	933	zinc-finger nucleases	T116,T126	C0597094
27832198	937	956	genetically dissect	T169	C0205239
27832198	962	968	allele	T028	C0002085
27832198	976	986	pathogenic	T033	C3816499
27832198	998	1027	asexual blood-stage infection	T046	C3714514
27832198	1029	1049	Comparative analysis	T062	C0683941
27832198	1053	1068	drug resistance	T038	C0013203
27832198	1073	1079	growth	T040	C0018270
27832198	1092	1113	recombinant parasites	T204	C0030498
27832198	1119	1126	express	T045	C0017262
27832198	1127	1133	Cam734	T028	C0017337
27832198	1137	1145	variants	T028	C0678941
27832198	1155	1158	Dd2	T028	C0017337
27832198	1176	1191	Southeast Asian	T083	C0003983
27832198	1192	1199	variant	T028	C0678941
27832198	1205	1214	wild-type	T028	C1883559
27832198	1215	1220	pfcrt	T028	C0017337
27832198	1260	1265	PfCRT	T116,T123	C0962247
27832198	1266	1275	mutations	T045	C0026882
27832198	1290	1298	parasite	T204	C0030498
27832198	1326	1345	antimalarial agents	T121	C0003374
27832198	1383	1387	GC03	T028	C0017337
27832198	1388	1394	strain	T001	C1518614
27832198	1421	1426	pfcrt	T028	C0017337
27832198	1427	1434	studies	T062	C2603343
27832198	1488	1494	allele	T028	C0002085
27832198	1531	1537	Cam734	T028	C0017337
27832198	1548	1550	CQ	T109,T121	C0008269
27832198	1551	1561	resistance	T038	C0013203
27832198	1587	1592	A144F	T045	C0026882
27832198	1593	1601	mutation	T045	C0026882
27832198	1636	1650	Southeast Asia	T083	C0003983
27832198	1672	1679	impacts	T080	C4049986
27832198	1698	1704	Cam734	T028	C0017337
27832198	1715	1724	mutations	T045	C0026882
27832198	1728	1730	CQ	T109,T121	C0008269
27832198	1731	1741	resistance	T038	C0013203
27832198	1746	1754	parasite	T204	C0030498
27832198	1755	1767	growth rates	T079	C0449249
27832198	1769	1787	Biochemical assays	T059	C0005507
27832198	1805	1811	impact	T080	C4049986
27832198	1815	1821	mutant	T049	C0596988
27832198	1822	1827	PfCRT	T116,T123	C0962247
27832198	1828	1836	isoforms	T116	C0597298
27832198	1840	1848	parasite	T204	C0030498
27832198	1849	1859	metabolism	T040	C0025519
27832198	1871	1894	nucleoside triphosphate	T114	C0597106
27832198	1895	1901	levels	T080	C0441889
27832198	1903	1924	hemoglobin catabolism	T044	C1157963
27832198	1944	1948	heme	T109,T123	C0018966
27832198	1961	1978	digestive vacuole	T026	C1167024
27832198	1979	1985	volume	T081	C0449468
27832198	1990	1992	pH	T081	C0020283
27832198	2047	2070	complex molecular basis	T170	C4246449
27832198	2075	2088	physiological	T169	C0205463
27832198	2089	2095	impact	T080	C4049986
27832198	2099	2104	PfCRT	T116,T123	C0962247
27832198	2115	2127	antimalarial	T121	C0003374
27832198	2128	2143	drug resistance	T038	C0013203
27832198	2194	2199	pfcrt	T028	C0017337
27832198	2200	2207	alleles	T028	C0002085
27832198	2231	2239	efficacy	T080	C1280519
27832198	2254	2271	antimalarial drug	T121	C0003374
27832198	2272	2280	regimens	T061	C0040808